Revenue of $811.7 million; 12% reported growth; 13% organic growth GAAP EPS from continuing operations of $1.23; Adjusted EPS of $1.57 WALTHAM, Mass.–(BUSINESS WIRE)–Jul. 28, 2020– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the second quarter ended July 5, 2020. The Company reported... Read more
Detects two independent SARS-CoV-2 viral RNA targets from respiratory samples for increased confidence Differentiates SARS-CoV-2 from four other endemic human coronaviruses for specificity Validated with Bruker-Hain GenoXtract® NA and GenoXtract® 96 X3 nucleic acid extraction system and kits Validated with novel Bruker-Hain FluoroCycler® XT real-time PCR thermocycler NEHREN, Germany–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today... Read more
Research and training continues in Museu Nacional’s Laboratory of Archaeobotany and Landscape Dr. Scheel-Ybert (far left) with Rúbia Graciele Patzlaff, Leonardo Waisman de Azevedo and Taís Capucho. Museu Nacional is Brazil’s largest museum of natural history and cultural heritage and the oldest scientific institution in the country. It is part of the Federal University of... Read more
WASHINGTON, July 23, 2020 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the quarter ended July 3, 2020. All results in this release reflect only continuing operations unless otherwise noted. For the second quarter 2020, net earnings were $927.3 million, or $1.24 per diluted common share which represents a 38.0% year-over-year... Read more
WALTHAM, Mass., July 22, 2020 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 27, 2020. Second Quarter 2020 Highlights Second quarter revenue increased 10% to $6.92 billion. Second quarter GAAP diluted earnings per share (EPS) increased 5% to... Read more
Fully automated kit detects human antibodies of immunoglobulin class IgG to help identify individuals with adaptive immune response WALTHAM, Mass.–(BUSINESS WIRE)–Jul. 21, 2020– PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced the launch of a dry blood spot (DBS) based test for SARS-CoV-2 IgG using its GSP®/DELFIA® platform,... Read more
AUSTIN, Texas, July 20, 2020 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the company’s xMAP® SARS-CoV-2 Multi-Antigen IgG Assay. Clinical laboratories can now use this serology assay to identify the presence of antibodies in people who have been infected with the... Read more
WALTHAM, Mass. and VENLO, The Netherlands – July 16, 2020 – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leading global provider of Sample to Insight molecular diagnostics and sample preparation technologies, today announced that they have entered into an amendment... Read more
Two-dimensional (2D) materials such as transition metal dichalcogenides (TMDs) are receiving increasing attention due to their unique optical and electronic properties. Their possible applications include the production of transistors, photo detectors, light emitting diodes (LEDs) and photovoltaic cells. In order to produce high-quality devices, synthesis processes must be evaluated efficiently. Thus, non-destructive imaging techniques are... Read more
Roche will obtain co-development and co-commercialisation rights for pralsetinib, an investigational, precision therapy in late-stage development for people with RET-altered non-small cell lung cancer, various types of thyroid cancer and other solid tumours. Blueprint Medicines and Roche will collaborate on the development of pralsetinib. Roche and Blueprint Medicines will co-commercialise pralsetinib in the US while... Read more